Anna J Howard, Isabel Concepcion, Alice X Wang, Issam S Hamadeh, Malin L Hultcrantz, Sham Mailankody, Carlyn Rose Tan, Neha Korde, Alexander M Lesokhin, Hani Hassoun, Urvi A Shah, Kylee H Maclachlan, Sridevi Rajeeve, Heather J Landau, Michael Scordo, Gunjan L Shah, Oscar B Lahoud, David J Chung, Sergio A Giralt, Saad Z Usmani, Ross S Firestone
Outcomes for relapsed/refractory multiple myeloma (RRMM) patients have dramatically improved following the development and now growing utilization of B cell maturation antigen targeted chimeric antigen receptor (CAR) T cell therapy and bispecific antibody (BsAb) therapy. However, healthcare utilization as a quality-of-life metric in these growing populations has not been thoroughly evaluated. We performed a retrospective cohort study evaluating the frequency and cause of unscheduled healthcare interactions (UHIs) among RRMM patients responding to B-cell maturation antigen targeted BsAbs and CAR T cell therapies (N = 46)...
April 12, 2024: Blood Advances